JPS62179640A - Indication for end of efficacy of chemical - Google Patents

Abstract

PURPOSE:To enable visual recognition of the residual state and end point of chemical effect for volatile chemicals easily and accurately, by a method wherein a volatile desensitive chemical is mixed with an electron donative colorating organic compound and a developer to cause a color reaction between the colorating organic compound and the developer and changes in the color tone by the desensitive chemical is detected. CONSTITUTION:A volatile desensitive chemical such as pesticide, repellent, insecticide, sterilizer, and fragrance is made to coexist with crystal violet or other electron donative colorating organic compounds and bisphenol (A) or other developers. While the desensitive chemical exists sufficiently, the desensing action is greater than the action of the developer to inhibit color formation. As residual rate lowers with the volatilization of the chemical, a coloration starts with the reaction between the developer and the colorating organic compound, the color tone of the composition changes with the process of volatilizing the chemical. Thus, depending on the changes in the color tone, the residual state and end point of the efficacy of the chemical is visually recognized accurately.

Description

DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a method for indicating the end point of drug efficacy, and more specifically,
The present invention relates to a method for indicating the end point of drug efficacy in which the remaining state of drug efficacy of a volatile drug and its end point can be visually recognized by changes in color tone.

2. Prior Art Conventionally, a typical formulation that allows the degree of retention of efficacy to be visually recognized at room temperature and pressure is a typical example.

There are the following.

b) Sublimation insect repellent Solid insect repellents such as Balajichlorobenzene, naphthalene, and camphor gradually sublimate themselves at room temperature and normal pressure, so their size and state of disappearance vary when they are in the form of granules, tablets, and balls. The residual state of drug efficacy and its end point can be recognized.

(Gel-like aromatic solid gel containing fragrance, etc. using a water-soluble gelling agent allows the residual state of medicinal efficacy and its end point to be recognized by volatilizing the fragrance and water and reducing the solid substance.) I can do 1 thing.

A desiccant such as P1 desiccant silica gel absorbs moisture, and the chloride contained in the silica gel changes color to red, allowing the degree of retention of moisture absorption ability and its end point to be recognized.

The above-mentioned preparations themselves have properties and functions for displaying efficacy, making it possible to display their medicinal efficacy and ability.

However, most pharmaceuticals do not usually have the above characteristics and functions, and it is difficult to accurately recognize and display the residual state of drug efficacy and its end point, and it is difficult to find a method to do so. This is the current situation. In other words, it is in liquid form and is used by impregnating it into a holding body such as a porous material, and it changes into a different structure even if the liquid drug is volatilized or not volatilized. In many cases, the appearance of the carrier does not change at all before and after use, and for this reason, it is necessary to continue using a carrier whose medicinal efficacy has already disappeared, or
On the other hand, there are problems such as the drugs being discarded even though they still have residual medicinal properties.

As a countermeasure for this, generally, for example, after determining the expiry date of the drug in advance, by pasting a sticker with the usage and end dates printed on it, or by removing part of the printed part, the user is informed of the expiry date of the drug's effectiveness. 3 has been adopted as a means of informing the public.

In addition, although not under normal temperature and normal pressure, other methods of displaying drug efficacy include, for example, Japanese Patent Publication No. 46-24277, Japanese Patent Publication No. A6
-3F3599 discloses that by heating a dye-containing agent held in an impregnating material, the agent evaporates, the dye dissipates, and the color tone changes due to discoloration, and this can be used as an indication of efficacy. Disclosed.

Problems to be Solved by the Invention Among the conventional drug efficacy display means described above, in the case of a method of notifying the user of a predetermined drug expiration date, such as a method of pasting a sticker with printed usage and expiration dates, Drugs ν
Although the dispersion rate is quite different between, for example, the hot summer season and the cold winter season, it is necessary to replace it after a certain period of time. For this reason, the drug force in the holding body j
Continuing to use the drug even though it has disappeared and it is no longer effective, or conversely discarding the drug even though it has sufficient residual effect and is still effective. There is a problem that the three forces do not match for a certain period of time.

- If the change in color tone due to the volatilization of the chemical and the dissipation and discoloration of the dye are used as an indication of efficacy, it is necessary to cause the dispersion and discoloration of the dye by heating.
At normal temperature and pressure, color change S is obtained, and the problem is that only a broad indication of efficacy is possible. Furthermore, since the volatilization rate of the drug and the diffusion rate of the dye do not necessarily match, it is difficult to make adjustments to accurately display efficacy.

In this way, various efficacy labeling methods are being researched for preparations that do not have the characteristics and functions of efficacy labeling5. In many cases, the drug is only applicable, or the actual drug efficacy period does not match. By simply placing the formulated product under normal temperature and pressure, the user can clearly and accurately determine the residual state of the medicinal efficacy and its end point without adding any other external conditions. No method for indicating the end point has been found so far.

Therefore, an object of the present invention is to show a change in color tone during the effective period of volatile chemicals such as insecticides, repellents, insect repellents, fungicides, and fragrances, that is, in the process of volatilizing the chemical power. An object of the present invention is to provide a method for indicating the end point of drug efficacy, which allows the residual state and end point of drug efficacy to be visually and easily and accurately recognized.

Means for Solving the Problems In order to achieve the above-mentioned objective, the method for indicating the end point of drug efficacy according to the present invention combines an electron-donating color-forming organic compound and a color developer with a volatile desensitizing drug having various medicinal effects. coexist with the above-mentioned volatile desensitizing agent, causing a coloring reaction between the electron-donating color-forming organic compound and the color developer by volatilization of the above-mentioned volatile desensitizing agent, and causing a color tone change corresponding to the remaining state of the above-mentioned volatile desensitizing agent. It is characterized by making it possible to recognize the remaining drug efficacy and the end point of its efficacy.

Effect of the Invention The coloring mechanism and drug efficacy indicating function of the drug efficacy end point indicating method of the present invention will be explained.

The electron-donating color-forming organic compounds described above include those generally referred to as heat- and pressure-sensitive dyes. There are various types of this dye that are produced on an industrial scale, such as triphenylmethane-phthalide, fluoran, and phenothiazine dyes.For example, crystal is a triphenylmethane-phthalide dye. To briefly explain the principle of color development regarding violet lactone (CVL), the reaction mechanism of this dye with a color developer and a desensitizer is as follows.

Crystal violet lactone (CVL)
Crystal 1 Iolette (colorless)
(Blue) Crystal violet lactone itself is colorless, but due to the action of a color developer (e.g. bisphenol), the lactone ring in crystal violet lactone opens, becoming crystal violet and exhibiting a blue color.
Ru. - When a desensitizing agent (eg, esters, amides, etc.) acts, the opposite reaction proceeds, returning to the lacto/ring and becoming colorless.

The method for indicating the end point of drug efficacy of the present invention applies this coloring principle to indicating drug efficacy, and by causing a volatile desensitizing agent to exist in the electron-donating color-forming organic compound and the color developer. , before volatilization, that is, while the above-mentioned drug remains sufficiently, the desensitizing effect of the above-mentioned drug overcomes the action of the color developer and suppresses color development. When the above-mentioned ritual agent volatilized and the residual rate became low, the reaction force S between the color developer and the electron-donating color-forming organic compound started, and the color began to develop.Furthermore, the chemical agent completely volatilized and no longer remained. Sometimes exhibits a color tone characteristic of electron-donating color-forming organic compounds. Therefore, the reaction process described above corresponds to the volatilization process of the volatile desensitizing agent, and the remaining state of the efficacy of the volatile desensitizing agent and its end point can be visually recognized very accurately by the change in color tone of the composition. I can do it.

By impregnating, applying or holding a holder such as a pulp board with a color-forming drug composition containing the above-mentioned three components as essential components, the method of the present invention can be carried out easily, and its mechanism of action is not necessarily clear. In addition, stable color development is exhibited, and the stability of the drug and the electron-donating color-forming organic compound is increased over time.

Aspects of the invention Hereinafter, various aspects of the present invention will be explained in detail.

The volatile desensitizing agent used in the present invention is one that volatilizes under normal usage conditions (at normal temperature and pressure or under heating) and that develops a desensitizing effect on the electron-donating color-forming compound. Pyrethroid insecticides such as d-allethrin, empenthrin, flamethrin, ethoproxyfen, and resmethrin, dimethyl phthalate, diethyl phthalate, diptyl phthalate, diethyl fumarate, N,N-diethyl-m-)ramide, etc. Insect repellent/repellent, ethyl benzoate,
Insect repellent fragrances such as 70-l, insaflor, eugenol, citronellol, anethole, carvone, citral, citronellal, nerol, keraniol,
Examples include fragrances such as linalyl acetate, acetophenone, terpineol, menthone, benzyl benzoin, ethyl phenylacetate, isoamyl acetate, and eucalybutol, and insect repellents and fungicides such as cinnamic aldehyde and benzaldehyde.

The above-mentioned drugs are compounds that have various effects such as insecticidal, insect repellent, repellent, attractant, fragrance, deodorizing, antibacterial, antifungal, and sterilizing effects. Various compounds that volatilize and exhibit their effectiveness can be used, and depending on their medicinal efficacy, they can be used as insecticide compositions, insect repellent compositions, aromatic deodorant compositions, etc., and depending on their volatilization characteristics, they can be used as agents that volatilize at room temperature, or when heated. Used for various purposes as fumigation agent, etc.
I can do things. Moreover, it goes without saying that each drug may be used alone or in combination with 28i or more.

It is preferable that the above-mentioned volatile desensitizing agent can be uniformly dissolved or fused with the electron-donating color-forming organic compound and/or color developer, but if it is insoluble or poorly soluble, a solvent may be used. The solvent may be one that uniformly dissolves the above-mentioned drug, electron-donating color-forming organic compound, and color developer, and that keeps the dissolved substance stable over time, such as aliphatic hydrocarbons, aromatic compounds, etc. group hydrocarbons, halogenated hydrocarbons,
Examples include alcohols, esters, ethers, ketones, and amides.

If the volatilization rate of the drug and the solvent are significantly different, it may cause problems such as making it difficult to accurately display the drug efficacy.
be. In this case, it is sufficient to use a solvent that does not have a large difference in volatilization rate between the chemical and the solvent. The solvent itself may or may not have medicinal properties.

Examples of the electron-donating color-forming organic compounds used in the present invention include triphenylmethane phthalides, fluorans, phenothiazines, indolyl phthalides, spiropyrans, leucoaulamins, rhodamine lactams, etc. Examples include malachite green lactone, crystal violet lactone, rhodamine lactone, 3
-diethylamino-6#8-dimethylfluorane, 3-
Cyclohexylamino-6-chlorofluorane, 2-,
,'thyl-6-(N-1)-tolyl-N-ethylamine)fluoran, 3-diethylamine-6-methyl-7-
Chlorofluorane, 3-diethylamine-7-medoxyfluorane, 3-diethylamino-6-benzyloxyfluorane, 3-diethylamino-6-methylfluorane, 3-diethylamine-7-chlorofluorane, 3-
Diethylamine-5-methyl-7-(N,N-dibenzylamino)fluorane, 3-diethylamine-6-methyl-7-anilinofluorane, 3-diethylamino-7
-chloroanilinofluorane, 3-pyrrolidino-6-methyl-7-anilinofluorane, 3-(diethylamino)-7-(N,N-dibenzylamino)fluorane, 3
-piperidino-6-methyl-7-anilinofluorane,
3.6-bis(diethylamino)fluoran-r-(4
'-Nitroanilino)lactam, 3-(N-cyclohexyl-N-methylaminoco6-methyl-fuanilifluorane, 2,3-butylene-6-di-n-butylaminofluorane, 3-diethyl-7-( p-) Luigino)
Fluoran, 3-diethylamino-7-(N-methylanilino)fluorane, 3-dimethylamine-6-medoxyfluorane, 1,2-benz-6-diethylaminofluorane, 3,6-ethoxyfluorane, 3- Dimethylamine-6-methyl-7-chlorofluora/, 1.2
-Benz-6-diethylaminofluorane, N-phenylrhodamine lactam, 2-(3,6-bis(diethylamino)-9-(0-chloroanilino)xanthyl]benzoic acid lactam, 2-(phenyliminoethanezylidene)- 3,3-dimethylindoline gr-methoxy-N
-3,3-)limethylindolinobenzosviropyran,
N-3,3-)! JMethi#indolinobenzospirobilane, 1.3.3-trimethylindoline-2,2'-spiro-6'-nitro8'-methoxybenzobilane, I
, 3゜3-) 'J mefruindolino7'-chlor-β-naphthospiropyran, di-β-naphthospiropyran, benzo-β-naphthospiropyran, xantho-β-naphthospiropyran, N-acetyloramine , N-phenyluramine, rhodamine B lactam, benzoylleucomethylene blue, methylleucomethylene blue, ethylleucomethylene blue, methoxyhensoylleucomethylene blue, etc., and they may be used alone or in combination of two or more. As the electron-donating color-forming organic compound, various conventionally known compounds can be used as long as they remain without being volatilized in the use state of the pharmaceutical composition and are non-volatile or volatile.

The above electron-donating color-forming organic compounds are colorless or light-colored when used alone, and develop color T when a color developer S is present. Examples of color developers used in the present invention include 2,2-bis(4'-:)'o bovine diphenylpropane, 3,3'-thiodipropionate simiristyl, 2
．． 2'-methylenebis(4-chlorophenol), 4,
4'-methylenebis-2x 6-c-t-butylphenol, 2,4.6-)lis(3',5'-di-t-
Butyl-4'-hydroxybenzyl)mesitylene, 4.
4'-thiodiphenol, 4,4'-bis(4-hydroxyphenyl)sulfone, butylidenebis-6-t-butyl-m-cresol, p-phenylphenol, 1.
1.3-tris(2-methyl-4-hydroxy-5-1
-butylphenyl)butane% 3e5-di-t-butylcatechol, catechol, p-t-": jf catechol, methyl gallate, phenyl salicylate, salicylanilide, p-octylphenyl salicylate, flJ chill #p-t- Butylphenyl, 2-hydroxy-4-methoxybenzophenone, 2.7.4.4'-tetrahydroxybenzophenone, 2.2'-dihydroxy-4-methoxybenzophenone, 2.2'-dihydroxy-4,
4'-dimethoxybenzophenone, 2,4-dihydroxybenzophenone, 2-hydro-4-n-octoxybenzophenone, β-naphthol, p-cresol,
Hydroquinone, cyanisole in butylhydro, 6-t
-Butyl-2゜4-xylenol, p-hydroxybenzyl alcohol, 0-t-butylphenol, t-butylhydroquinone, 2-t-butyl-6-methylphenol, 2 #5-Seal t-7"5-ylhydroquinone , propyl p-hydroxybenzoate, 1.2.4
-1-lyhydroxybenzene, 1,2°3-benzotriazole, and isotonic S, and various conventionally known color developers that are non-volatile or hardly volatile in the sense described above can be used. The above color developers may be used alone or in combination of two or more. Among these color developers, there are many compounds that are useful as antioxidants and ultraviolet absorbers when mixed into drugs.
If a color developer having such an effect is used, it will be effective in stabilizing the drug.

In the present invention, the blending ratio of the volatile desensitizing agent, the electron-donating color-forming organic compound, and the color developer is usually as follows in the weight ratio: drug: electron-donating color-forming organic compound: color developer = l OO:
0.1-50: About 0.01-100 is sufficient. The greater the amount of the electron-donating color-forming organic compound, the higher the coloring density will be, but if it is too much, it will be difficult to mix uniformly, f# solution, suppress volatilization of the drug, and develop electron-donating color. This is not preferable because it causes problems such as contamination with organic compounds and the like. - In the case of the color-forming drug composition of the present invention, especially in the case of a carrier impregnated with the composition, it is better to increase the amount of the color developer because the overall color density is low, but if it is in excess, it will be uniform. This is not preferable because it causes problems such as poor mixing, poor dissolving power, and unstable color development. Therefore, the preferred range of the above blending ratio is lOO: 0.2
-30: 0.1-50.

As explained in the above section "Actions of the Invention," the color-forming drug composition of the present invention suppresses color development of an electron-donating color-forming organic compound by a color developer using a volatile desensitizing agent. , which causes coloration due to volatilization of the above-mentioned chemical.

Therefore.

Whether or not the electron-donating color-forming organic compound produces a color depends on the reactivity (desensitization) of the desensitizing agent and the reactivity (color development) of the color developer. While the above-mentioned drug remains, it is necessary to suppress the coloration of the electron-donating color-forming organic compound. Therefore, if the drug itself has a weak fluency, it is best to use a color developer with a weak effect or a desensitizing solvent to compensate for the desensitization of the drug. It is also possible to use three solvents. However, if the volatilization rates of the volatile desensitizing drug and the desensitizing solvent are significantly different, it may be difficult to accurately display drug efficacy.
A similar volatilization rate is preferable because it becomes difficult.

Such volatile and desensitizing solvents include acetone, methyl ethyl ketone, diethylene glycol dimethyl ether, methyl acetate, ethyl acetate, n-butyl acetate, isoamyl acetate, n-octyl acetate, dimethyl fumarate, and n-caproic acid. Methyl, n-methyl caprate,
Methyl laurate, dioctyl adipate, n-propyl salicylate, ethyl myristate, n-cabric acid
-amyl, inbutyl undecanoate, inbutyl laurate, ethyl laurate, isoamyl n-caproate,
Dibutyl adipate, butylcarpitol, n-7'can, I, l.

1-trichloroethane, coconut oil, triethylamine, dimethylamine, acetonitrile, 1°4-dioxane,
Examples include n-octyl alcohol, toluene, morpholine, dimethyl glycol and other ketones, ethers, esters, alcohols, hydrocarbons, and amines.

The colors that can be obtained with electron-donating color-forming organic compounds include red, black, and! Since most colors such as green, purple, orange, yellow, and brown can be obtained, it is necessary to add an electron-donating color-forming organic compound and a color developer to the drug for stool use, if necessary. By selecting the solvent, it is possible to obtain the desired color tone, color density and chromaticity period.

Further, by adding a coloring agent such as a general oil-soluble dye, it is possible to change the color from one color to another. -For example,
100 parts of repellent N,N-diethyl-m-)ruamide, 1 part of oil-soluble dye Eizensviron Blue GNH, 1 part of electron-donating color-forming organic compound NC-R-1 (fluoran compound), and color developer bisphenol. When 2 parts of the mixed bath solution is applied to a linter mat and left to stand at room temperature, the color quality S changes from blue to evening purple to reddish violet depending on the volatilization of the repellent.

If the drug is not of the type that gradually volatilizes to exert its effect, it can also be used for, for example, a drug that sublimes or does not sublimate but gradually decomposes and loses its effectiveness.

That is, in the former case, by sublimation, and in the latter case, by decomposition, the desensitizing power of the drug itself is weakened, and the color developing ability of the color developer is strengthened, so that color can be gradually developed. It is also possible to use a suitable volatile solvent having a volatilization rate that matches the decomposition rate of the drug so that the color develops as the drug evaporates. Therefore, in the present invention, one volatile drug refers to a drug that volatilizes without being decomposed under conditions of use (at room temperature and normal pressure and under heating), as well as IzIGt-degradable drugs that have sublimation properties. The term "volatile" refers to the state in which the drug escapes from the color-forming reaction system, and should be interpreted as a broad term.

When carrying out the method of the present invention, ultraviolet absorbers, antioxidants, desensitizers, sensitizers, synergists, volatilization regulators, etc. may be added as necessary.

Furthermore, when carrying out the method of indicating the end point of drug efficacy of the present invention, it is desirable to use a carrier in order to obtain effective and effective indication of efficacy. By using a holding body,
Liquid volatile drugs can be handled as solids, which can reduce contamination, clarify the color quality of drug compositions, and in some cases improve stability over time. .

The above-mentioned holding body may be any type as long as it can stably hold the pharmaceutical composition and the color quality can be visually determined,
Paper, non-woven fabric, cloth, wood, pulp, inorganic polymeric substances, inorganic porous substances (silicate, silica, zeolite, etc.), organic polymeric substances (cellulose, polyethylene, polyvinyl chloride, holiflobyrene, polyvinyl alcohol, vinyl acetate) -vinyl chloride copolymer, styrene-divinylbenzene copolymer, etc.), gelling substances (agar, carrageenan, starch, gelatin, alginic acid, etc.), sublimable substances (adamantane, cyclododecane, norbornane, trimethylnorbornane, endotris), methylene norbornane, paradichlorobenzene, naphthalene, camphor JJl), etc., and these can be used alone or in combination of two or more, and can be used in matte, sheet, film, gel, powder, granule, or tablet shapes. It can be used in any dosage form.

In manufacturing the efficacy-indicating drug carrier of the present invention,
Drop coating, dipping coating, spray coating, printing,
Methods such as brushing or pasting on a holder can be used, and if the drug to be used is not S liquid or does not use a solvent, it can be obtained by methods such as kneading, mixing and melting. The mixture can be kneaded into a holder and applied by coating, printing, etc., or it can be directly formulated into a gel, powder, granule, etc.
can. Also, when the mixture is applied to a holding body by coating, impregnating, etc.

The holder can be coated or impregnated over the entire surface, partially, in spots, on one side, or in a pattern.

The concentration of the drug composition contained in the carrier may be determined as long as the desired color quality occurs and can be visually determined, and depends on the color of the carrier itself.
1 (or saturation retention t) of 10 to go is appropriate. For example, when a saturated 1iIL+, 5S+ mat made by Linter (plain white) is impregnated with a pharmaceutical composition of 100 parts of N,N-diethyl-m-)ylamide, 11 parts of NC-R-1, and 2 parts of bisphenol. If the applied amount is less than about 0.17, the diffusion of the drug composition into the mat will be poor (and the color density after whitening will be low, making it difficult to distinguish the state of coloration.On the other hand, if the applied amount is close to the saturation amount, The drug composition may ooze out, causing problems such as contamination. However, if the drug composition liquid does not permeate or diffuse into a carrier such as metal, plastic, or synthetic paper, or if the drug composition does not penetrate or diffuse (solid), In the case of spot coating or printing on a composition containing an inorganic substance, a polymeric substance, etc. (such as a liquid or semi-fluid substance), the above range may not be applied. When an elongating agent or the like is used as a carrier, it is not possible to retain (contain) the pharmaceutical composition at a high concentration.In such cases, it is recommended to retain the drug composition in an adsorbent material with high retention capacity and then mix it in. can.

The holding body may contain a binder, an antioxidant,
Ultraviolet absorbers, dispersants, fixing agents, etc. can be added. Further, the carrier itself may have a color, and in this case, a color quality ranging from one color to another can be obtained.

When using the efficacy-indicating drug carrier of the present invention, if it is necessary to prevent contamination due to color migration, packaging with breathable non-woven fabric, paper, cloth, film, etc., as necessary. Storage in plastic containers, paper containers, etc.
Alternatively, coating treatment, lamination processing, etc. can be applied, and the product form can be selected as appropriate depending on the intended use.

EXAMPLES The method for indicating the end point of drug efficacy of the present invention will be specifically explained with reference to Examples below.゛Examples 1 to 13 (2) Various drugs and fragrances with various medicinal effects, IB + various electron-donating color-forming organic compounds, and IcI color developer (bisphenol) were mixed into (AJ: (Bl: (Cn= l
OO: mixed and dissolved at a weight ratio of 2:4, linter pine)
(2,0 dragon thickness, 2.2 x 3.5 cm) 0.5
F-coated Tamono veneer box (inner volume approx. 9001cm)
) and volatilized at room temperature to examine the relationship between the color quality of the mat and the drug residual rate over time. The results are shown in Table 1. In the table below, the meaning of each symbol T indicating the state of color quality is as follows.

Human: No color quality at all.

B: The four corners of the mat had a dull color.

C: The entire mat had a tingling color.

D: Overall matte strength S: Clear and deep color.

In addition, the drug residual rate is determined by the following formula.

As is clear from Table 1 above, the color quality of the matte is caused by the volatilization of the volatile desensitizing agent.The color quality does not change gradually from the start of volatilization, but rather depends on the amount of the agent in the matte. Color quality S starts only when it becomes considerably less. That is, since it is a short time from the start of the color quality to the end of the color appearance, the end point force S of the effect can be recognized very accurately.

Examples 14 to 16 Each drug with various medicinal effects, each IBI a [11 child-donating color-forming organic compound and (C1 color developer (bisphenol A)) (Al: IBI: 1 cl = +00:2:4
Mix and dissolve at a weight ratio of
z 2 x l 5 cm) coated with O, 5 F was heated with a heater at 100 to 150 °C to volatilize the chemical, and the color quality of the matte was determined as the heating time increased in the same manner as in Examples 1 to 13. The relationship between this and the drug residual rate was investigated. The results are shown in Table-2.

Effects of the Invention As described above, the method for indicating the end point of medicinal efficacy according to the present invention has various effects such as repellent, insect repellent, insecticidal, antifungal, and sterilizing, as well as aromatic properties.
An electron-donating color-forming organic compound and a color developer are made to coexist in the volatile desensitizing agent used in VT, and the electron-donating color-forming property of the color developer is maintained while the volatile desensitizing agent remains sufficiently. It suppresses reaction to organic compounds to suppress coloration, and causes coloration by volatilization of the above-mentioned chemical.

Therefore, the residual state of drug efficacy and the end point of its efficacy can be visually and extremely accurately recognized by the above-mentioned color change.
It is possible to eliminate all at once the problems that have arisen in fields where volatile drugs have been used due to unclear and inaccurate endpoints of drug efficacy. Furthermore, when carrying out the method of the present invention, each of the above-mentioned components is mixed with cloth, cloth, and pulp.

It can be easily carried out by impregnating, coating or retaining porous substances, polymeric substances, gelatinous substances, etc., and this also makes it possible to treat liquid volatile drugs as solid substances.
This not only makes it possible to prevent staining, but also to obtain stable coloring, making the color quality clearer, and further improving the stability of each of the above components over time.

Claims (1)

[Claims] An electron-donating color-forming organic compound and a color developer are made to coexist in a volatile desensitizing agent, and the coloring reaction between the electron-donating color-forming organic compound and the color developer is caused by volatilization of the volatile desensitizing agent. A method for indicating the end point of drug efficacy, characterized in that the remaining state of drug efficacy and the end point of the drug efficacy can be recognized by changing the color tone corresponding to the remaining state of the volatile desensitizing drug.